<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03868618</url>
  </required_header>
  <id_info>
    <org_study_id>CL-GEN-002033</org_study_id>
    <nct_id>NCT03868618</nct_id>
  </id_info>
  <brief_title>Dual-sided Hypoglossal neRvE stimulAtion for the treatMent of Obstructive Sleep Apnea</brief_title>
  <acronym>DREAM</acronym>
  <official_title>A Multicenter Study to Assess the Safety and Effectiveness of the Genio Dual-sided Hypoglossal Nerve Stimulation System for the Treatment of Obstructive Sleep Apnea in Adults Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nyxoah S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nyxoah S.A.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter study to assess the safety and effectiveness of the Genio dual-sided
      hypoglossal nerve stimulation system for the treatment of obstructive sleep apnea in adults
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of device-related SAEs</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of device-related SAEs recorded during the study for a period of 12 months post-surgery.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Apnea Hypopnea Index (AHI4%)</measure>
    <time_frame>12 months</time_frame>
    <description>percentage of responders at 12 months based on AHI4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Oxyhemoglobin Desaturation Index (ODI4%)</measure>
    <time_frame>12 months</time_frame>
    <description>percentage of responders at 12 months based on ODI4</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Genio Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Genio™ system is an implantable neurostimulation system comprised of one implanted device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Genio™ system</intervention_name>
    <description>The Genio™ device is a permanent implant. It is implanted in the chin area and delivers stimulation to both hypoglossal nerve branches (i.e., the left and right branches). The implant does not include a battery or an embedded software and is externally powered.</description>
    <arm_group_label>Genio Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) limitations

          -  Likely suffer from moderate to severe OSA based on history and physical

          -  Has either not tolerated, has failed or refused positive airway pressure (PAP)
             treatments

          -  Willing and capable of providing informed consent

        Exclusion Criteria:

          -  Inadequately treated sleep disorders other than OSA

          -  Significant co-morbidities that contraindicates surgery or general anesthesia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 7, 2019</study_first_submitted>
  <study_first_submitted_qc>March 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2019</study_first_posted>
  <last_update_submitted>June 23, 2020</last_update_submitted>
  <last_update_submitted_qc>June 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

